...
首页> 外文期刊>Research journal of pharmacy and technology >Application of 32 Factorial Design in the Formulation of Fast Release Olmesartan Medoxomil Liquisolid Tablets
【24h】

Application of 32 Factorial Design in the Formulation of Fast Release Olmesartan Medoxomil Liquisolid Tablets

机译:32因子设计在快速释放奥美沙坦美多索密液固体片剂中的应用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Fast dissolving tablets are gaining more importance in the market day by day and are available in the market for treating many disease conditions. Olmesartan medoxomil (OLM) is the novel antihypertensive drug having specific angiotensin II type 1 antagonist activity and used in the management of acute and chronic hypertension. Rapid onset of action is desirable to provide fast relief in the treatment of heart failure. Hence, it is necessary to enhance dissolution rate of OLM to obtain faster on set of action, minimize the variability in absorption, and improve its overall oral bioavailability. Liquisolid technique was used to enhance the aqueous solubility and dissolution rate to obtain faster on set of action, minimize the variability in absorption, and improve its oral bioavailability. The aim of the present study was to formulate OLM liquisolid tablets. A 32factorial design was applied to investigate the combine effect of Neusilin US2 (carrier material) and Aerosil 200 (coating material). The angles of repose and % drug release were selected as dependent variables. Liquisolid systems of OLM were evaluated for pre and post compression parameters. In vitro drug release studies showed highest drug release at initial bursting of tablet at 2 min. The results of a 32 full factorial design revealed that the amount of Neusilin US2 and Aerosil 200 significantly affect the dependent variables, angle of repose and % drug release. Higuchi model was found to be the best fit model for the optimized batch. Thus Neuslin US2 should be in high concentration and Aerosil 200 should be in low concentration i.e high R value which gives the enhanced solubility and hence fast dissolution i.e. onset of action is obtained.
机译:速溶片剂在市场上日益重要,并且在市场上可用于治疗许多疾病。 Olmesartan medoxomil(OLM)是具有特定血管紧张素II 1型拮抗剂活性的新型降压药,用于治疗急性和慢性高血压。需要快速起效以在心力衰竭的治疗中提供快速缓解。因此,有必要提高OLM的溶出速率,以更快地获得一组作用,最大程度地减少吸收变化,并提高其整体口服生物利用度。液固技术用于增强水溶性和溶解速度,从而在作用开始时获得更快的吸收,最小化吸收变化并提高其口服生物利用度。本研究的目的是配制OLM液体固体片剂。应用32因子设计来研究Neusilin US2(载体材料)和Aerosil 200(涂层材料)的结合效果。选择休止角和药物释放百分比作为因变量。对OLM的Liquisolid系统进行了压缩前后参数的评估。体外药物释放研究表明,在2分钟的片剂初次破裂时,药物释放最高。 32个全因子设计的结果表明,Neusilin US2和Aerosil 200的量会显着影响因变量,休止角和药物释放百分比。发现Higuchi模型是优化批次的最佳拟合模型。因此,Neuslin US2应该处于高浓度,而Aerosil 200应该处于低浓度,即高R值,这样可以提高溶解度,因此可以快速溶解,即起效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号